Pinnacle Biologics Inc.

Pinnacle Biologics Inc. is a specialty pharmaceutical company focused on improving patient outcomes through innovative biologic therapies and revitalization of older pharmaceutical brands. Pinnacle Biologics Inc. specializes in the development of biologic therapies aimed at serious health conditions.

The company was acquired by Concordia Healthcare in December 2013, with the financial terms of the deal not disclosed. Pinnacle's headquarters is located in Bannockburn, US. The founder's history is not publicly documented. Pinnacle Biologics is a specialty pharmaceutical company dedicated to enhancing the efficacy of critical therapies aimed at improving patient outcomes.

The company focuses on revitalizing older pharmaceutical brands while also facilitating the development of innovative therapies that target unmet medical needs. Their product offerings are primarily centered around biologics that address serious health conditions, providing healthcare professionals with life-changing treatment options. The company serves a diverse client base, including hospitals, clinics, and healthcare providers, ensuring that patients worldwide have access to these therapies. Pinnacle Biologics markets its products internationally, with particular emphasis on regions where there is an urgent need for advanced medical solutions, such as North America, Europe, and select emerging markets.

Pinnacle Biologics generates revenue through a combination of direct sales and partnerships with healthcare providers and institutions. The company's revenue model typically involves transactions between the firm and its clients, where hospitals and clinics purchase its pharmaceutical products directly for administration to patients. The pricing structure for Pinnacle Biologics' offerings is designed to reflect the innovative nature and therapeutic benefits of its products, with specific pricing tiers established for different therapeutic areas. Key products in their portfolio are tied to specific treatment protocols, and the company engages in strategic partnerships that enhance distribution and accessibility.

Through these channels, Pinnacle Biologics ensures a steady flow of revenue while supporting patient care initiatives across its targeted markets. Pinnacle Biologics plans to utilize its most recent funding round of USD 1. 50 mn to support the development and launch of new products aimed at addressing unmet medical needs. The company is actively exploring opportunities to expand into new geographic markets, particularly in Europe and select emerging markets, by the end of 2014.

The funding will also help reinforce existing partnerships and establish new collaborations within the healthcare sector to facilitate broader access to their therapeutic offerings.